Breaking News

WuXi PharmaTech Breaks Ground for New Changzhou Campus

May 9, 2014

Will provide early stage preclinical to commercial production

WuXi PharmaTech’s manufacturing subsidiary, Syn-The-All (STA) Pharmaceuticals Co., Ltd., began construction of a new R&D and cGMP manufacturing site in Changzhou, China. 
The new campus will be constructed in phases and include both research manufacturing and commercial manufacturing facilities. Phase one will double the company's current manufacturing capacity and is expected to be operational by 4Q15. Once the entire project is complete, the site will triple current capacity and employ approximately 1,500 chemists, production staff, and support staff.
"This project marks an important milestone in STA's mission of building a fully integrated API development and manufacturing platform," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "It furthers our commitment to providing partners worldwide with highly efficient and cost-effective solutions that help bring better medicines faster to patients."
  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus